Funding Status: IPO
Industry: End-to-End Drug Development
Estimated Revenue: $1M to $10M
Technology: Cancer
Number Of Exists: Post-IPO Equity
Headquarters: Hackensack, New Jersey, United States
Total Funding: 36800000.0
Last Funding Date: 2015-03-12
Last Funding Type: Post-IPO Equity
Investor Type: Company
Employee Number: 51-100
Investors Number: 4.0
Investment Stage: N/A
Founded Date: 1985-01-01